The European Medicines Agency, the European Union's drug regulator, on Friday found a possible link between Johnson & Johnson's COVID-19 vaccine and rare cases of blood clotting in deep veins.
During a Pharmacovigilance Risk Assessment Committee meeting, the agency said it found a possible link between venous thromboembolism and the J&J vaccine.
"VTE is a condition in which a blood clot forms in a deep vein, usually in a leg, arm or groin, and may travel to the lungs causing a blockage of the blood supply, with possible life-threatening consequences," the agency wrote in its meeting highlights.
The agency also recommends that immune thrombocytopenia be listed as a side effect of the J&J vaccine and AstraZeneca's vaccine.
ITP is a bleeding disorder in which "The immune system mistakenly targets blood cells called platelets that are needed for normal blood clotting," the agency wrote.
FDA announces key panel meetings on Moderna, J&J boosters, vaccines... Overnight Health Care - Presented by Altria - Merck's COVID-19 pill... While J&J said the conditions are rare, it will update the product information and continue to work closely with EMA and other government agencies, according to Reuters.
The vaccines from both AstraZeneca and Johnson & Johnson have previously been associated with rare incidents of blood clotting.
It's becoming increasingly difficult to discern fact from fiction, and unfortunately the media has a strong bias. They spin stories to make conservatives look bad and will go to great lengths to avoid reporting on the good that comes from conservative policies. There are a few shining lights in the media landscape-brave conservative outlets that report the truth and offer a different perspective. We must support conservative outlets like this one and ensure that our voices are heard.
Saturday, October 2, 2021
J&J vaccine could be linked to another clotting condition: EU
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment